Last reviewed 2026-04-20 · How we verify

Glustat (VOGLIBOSE)

Voglibose, marketed as Glustat, is an enzyme inhibitor used primarily for treating Type 2 Diabetes Mellitus, currently positioned in a competitive market with off-patent alternatives like acarbose and miglitol. Its key strength lies in its mechanism of action, specifically inhibiting Lysosomal alpha-glucosidase, which differentiates it from other alpha-glucosidase inhibitors. The primary risk to Glustat is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.

At a glance

Approved indications

• Diabetes mellitus type 2
• Glucosylceramide beta-glucosidase deficiency

Common side effects

No common side effects on file.

Key clinical trials

• A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients (PHASE3)
• Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients (PHASE3)
• Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes (PHASE4)
• Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes (PHASE4)
• Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"
• Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015) (PHASE3)
• Assessment of an Alpha-glucosidase Inhibitor to Block Cardiac Events in Patients With MI and IGT (NA)
• MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.